Hetergeneous tumour response to photodynamic therapy assessed by in vivo localised 31P NMR spectroscopy.
Photodynamic therapy (PDT) is efficacious in the treatment of small malignant lesions when all cells in the tumour receive sufficient drug, oxygen and light to induce a photodynamic effect capable of complete cytotoxicity. In large tumours, only partial effectiveness is observed presumably because of insufficient light penetration into the tissue. The heterogeneity of the metabolic response in mammary tumours following PDT has been followed in vivo using localised phosphorus NMR spectroscopy. Alterations in nucleoside triphosphates (NTP), inorganic phosphate (Pi) and pH within localised regions of the tumour were monitored over 24-48 h following PDT irradiation of the tumour. Reduction of NTP and increases in Pi were observed at 4-6 h after PDT irradiation in all regions of treated tumours. The uppermost regions of the tumours (those nearest the skin surface and exposed to the greatest light fluence) displayed the greatest and most prolonged reduction of NTP and concomitant increase in Pi resulting in necrosis. The metabolite concentrations in tumour regions located towards the base of the tumour returned a near pre-treatment levels by 24-48 h after irradiation. The ability to follow heterogeneous metabolic responses in situ provides one means to assess the degree of metabolic inhibition which subsequently leads to tumour necrosis.
Ceckler
T L
TL
Department of Biophysics, University of Rochester School of Medicine and Dentistry, New York 14642.
Gibson
S L
SL
Kennedy
S D
SD
Hill
R
R
Bryant
R G
RG
D000818:Animals; D017323:Dihematoporphyrin Ether; D005260:Female; D006415:Hematoporphyrins / Q000627:therapeutic use*; D006863:Hydrogen-Ion Concentration; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D009336:Necrosis; D010710:Phosphates / Q000378:metabolism; D010758:Phosphorus; D010778:Photochemotherapy; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D051381:Rats; D011916:Rats, Inbred F344; D012265:Ribonucleotides / Q000378:metabolism
D006415:Hematoporphyrins; D010710:Phosphates; D011838:Radiation-Sensitizing Agents; D012265:Ribonucleotides; D010758:Phosphorus; D017323:Dihematoporphyrin Ether